Summary of State of Immunotherapy, especially Immune Checkpoint Inhibitors

By Ravi A. Madan, MD, and William L. Dahut, MD

Although immunotherapies are poised to permanently reshape treatment for bladder and kidney cancers, immune-based therapeutics research in prostate cancer has stagnated. There is immunotherapy available for prostate cancer, however, the delayed effects of treatment and the rare effect on prostate-specific antigen (PSA) levels have generated less enthusiasm compared with the rapid and sustained responses in some patients with bladder and kidney cancers who have been treated with immune checkpoint inhibitors. In addition, recent negative results of some trials have raised more concerns about the lack of potential for immunotherapy in prostate cancer. Nonetheless, several ongoing studies of immune checkpoint inhibitor combinations are potentially defining a course for immunotherapy development.

Read the article here

FDA Approves Foundation Medicine’s FoundationOne CDx Comprehensive Genomic Profiling Test

FDA has approved the FoundationOne CDx (F1CDx) cancer biomarker assay concurrently with a decision from the Centers for Medicare & Medicaid Services (CMS) to provide insurance coverage for the next-generation sequencing (NGS)-based in vitro diagnostic (IVD) test.

FDA Approves Foundation Medicine’s FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics.

Read more about it here

US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

US Too Prostate Cancer Panel Discussion and Webcast on Advanced Prostate Cancer

  • Presented by: Bayer
  • Sponsored by: Dendreon and Jannsen Oncology
  • In Kind Sponsor: Los Padres
  • Guest Speakers:
    • Dr. Edwin Morales – Urology Specialist, San Antonio
    • Dr. Michael Liss – Urologist, Urologic Oncologist, and Lead Prostate Cancer Researcher at UT Health, San Antonio
    • Dr. Vijay K. Gunuganti – Medical Oncologist at Texas Oncology
    • Moderator: Dr. Juan A. Reyna – Staff Physician at Audie L. Murphy Memorial VA Hospital; and Clinical Faculty at UT Health

Watch the recording here

Dr. Mark Scholz and Panel Discussion Video – El Camino Hospital

Dr. Mark Scholz participated in a tumor board session with a discussion of Prostate Cancer Cases at El Camino Hospital in November 2017.

Participants included:

  • Robert Sinha, MD, Medical Director of Radiation Oncology
  • Frank Lai, MD, Urological Oncologist/Robotic Surgeon, El Camino Hospital
  • Steven Kurtzman, MD, Radiation Oncologist, Director of Prostate Brachytherapy, El Camino Hospital
  • Shane Dormady, MD PhD, Medical Director of Oncology, El Camino Hospital
  • Mark Scholz, MD, Medical Oncology, Director of Prostate Cancer Specialists, Founder of Prostate Cancer Research Institute

View the recording of the event here